


DIGIPATH DISPATCH

Gestalt Company Newsletter



FROM INNOVATION TO IMPLEMENTATION: TRUST, STANDARDS, & OPERATIONAL EFFICIENCY

By Lisa-Jean Clifford, President

In 2025, pathology is no longer waiting for digital and AI to prove themselves, they have been, and are actively being, rolled out and embedded into clinical workflows. But for digital and AI to truly take hold, labs need more than the technical solutions: they need to support and drive adoption. By deploying easy-to-use solutions you provide pathologists with control, confidence, and interoperability.

Maturing AI: From Promise to Practice

Many AI solutions still function as independent applications or add-ons. That's not good enough or secure enough. To be transformative, AI must be integrated inside the pathologist's workflow as a visible, interactive, and actionable tool.

PathFlow®, our pathologist-focused digital platform, optimizes workflows for a streamlined environment. We are leveraging the power of AI, voice recognition, and automation to transform anatomic pathology laboratories from glass slides, microscopes, and couriers to a fully interoperable, automated, digital workflow.

(Continued on page 2)

Newsletter Highlights

[AI Innovation and Implementation](#)

[An Industry First: PathFlow Version 6](#)

[Partnerships & Advancing Digital Pathology](#)

[Industry Expertise & Thought Leadership](#)

[Join Us at DP-AI Workshop 9.0](#)

[Continuing A Record of Compliance Excellence](#)

[A Message from CEO](#)

FROM INNOVATION TO IMPLEMENTATION: TRUST, STANDARDS, & OPERATIONAL EFFICIENCY (CONT'D)

Enabling Trust, Validity & Efficiency

Technology is only part of the solution. In today's climate, adoption depends upon transparency, validation, governance, and regulatory alignment.

Recent regulatory changes underscore this: with the FDA's rollback of its 2024 LDT oversight rule (Sept 19, 2025), labs again retain clearer authority to develop and validate in-house tests. This reinforces the value of deploying innovative, open solutions.

AI is no longer a vision - it's becoming integral. But true transformation happens when pathologists trust, validate, and control it. At Gestalt, we build that bridge.



"Our partnership with Gestalt marks a pivotal step in advancing digital pathology across clinical, educational, and research domains," said Dr. Christopher Gaudette, DVM, ADDL.

"PathFlow's robust capabilities align perfectly with our commitment to innovation, diagnostic, and academic excellence. We look forward to expanding this collaboration with a focus on collaboration around AI development and integration."

AN INDUSTRY FIRST

INTRODUCING PATHFLOW VERSION 6: BUILT FOR THE DEMANDS OF MODERN PATHOLOGY AND THE FUTURE OF PRECISION MEDICINE

We are excited to announce the [release of PathFlow Version 6](#), the latest evolution of Gestalt's award-winning digital pathology platform. This major update is designed to meet the demands of modern pathology by improving speed, clarity, and collaboration.

The Industry's First Fully Speech-Enabled Digital Solution

[Gestalt has partnered with Voicebrook](#), to deliver seamless integration between our award-winning digital platform, PathFlow, and their industry-leading reporting solution, VoiceOver PRO. This collaboration provides significant efficiency gains, flexibility and collaboration.

Version 6 is available now for both existing customers and new partners!



**OmniPathology and Gestalt
Together are Building a
Future of Accessible, AI-
Driven Diagnostics Globally**

[OmniPathology has chosen Gestalt](#) as its strategic digital pathology partner, leveraging the power of PathFlow to accelerate innovation and extend high-quality diagnostics to more communities worldwide.



**Tulsa Medical Lab Ushers in
a New Digital Era with
Gestalt to Drive Digital
Pathology Innovation**

[Tulsa Medical Lab \(TML\) has selected PathFlow®](#) as their digital pathology solution, marking a major step forward in the lab's strategy to streamline operations, enhance diagnostic accuracy, and accelerate the adoption of AI-driven workflows.

INDUSTRY EXPERTISE & THOUGHT LEADERSHIP

Early detection, better outcomes: Advancing diagnosis in men's health

Featured in MLO | By Lisa-Jean Clifford

Earlier diagnosis can change lives. This article explores how digital pathology and AI-driven workflows are helping improve detection, accuracy, and outcomes in men's health.

Preparing Your Lab's Automation Infrastructure for Digital Pathology & AI

Featured in MLO | By Lisa-Jean Clifford

This article provides labs with a roadmap to guide them in preparation of deploying digital and AI solutions.

What 10 Large U.S. Labs Say About Their Digital Pathology Journeys

Featured in CAP Today | By Lisa-Jean Clifford

Ten of the largest labs in the U.S. shared how they moved from plans to production—revealing timelines, key barriers (IT, slide quality, workflow), and lessons learned in adoption.

CONTINUING OUR RECORD OF COMPLIANCE EXCELLENCE

By Spencer Metz, SOC/DevOps Engineer

During Q3, Gestalt's compliance group focused on our annual SOC 2 and HIPAA audits, conducted by a third-party auditing firm. As part of the annual audit, we completed our Risk Assessment and internal audits, and planned for other areas over the upcoming year to continue to strengthen our overall compliance posture.

As of mid-October, we've completed the SOC 2/HIPAA audit fieldwork in record time and are awaiting the final report from our auditors after having been notified that we are, as always, compliant.

Additionally, we have been implementing ISO 27001 and ISO 13485 controls and policies into our compliance framework during the quarter, with our ISO 27001 audit scheduled for mid-November.

Integration, Interoperability, and Today's Lab of the Future

DP-AI Workshop 9.0 | Chicago, IL | Nov. 6-8

Gestalt is joining industry leaders in pathology and AI at the DP-AI Workshop 9.0 in November to **expand the horizons of digital pathology**.

Are you attending? Connect and discuss AI-ready platforms built for real-world labs with Lisa-Jean Clifford.

A Message from the CEO

At Gestalt, progress is always shared. It's built through collaboration, innovation, and trust with our partners and customers. This quarter, we've seen the digital pathology landscape move forward in powerful ways: the FDA's rollback of its LDT rule reaffirmed lab autonomy and innovation, major scanner vendors have leaned into DICOM-first interoperability, and validated AI models are making their way into real-world workflows.

These shifts reinforce exactly what drives us: empowering pathologists with intelligent, interoperable, and trustworthy solutions.

Our team remains focused on ensuring our solutions continue to bridge technology and practice, helping labs adapt quickly while maintaining control and compliance.

As we look ahead, we are excited to share what's next, especially our continued collaboration with pathologists, partners, and innovators across the field. Together, we are not just following the evolution of digital pathology; we are shaping it.

Onward and upward.

- DR

